GH: Expanded G360 Panel Approved Earlier Than Expected; ADLT Timeline Potentially Accelerates

Research evidence excerpt

GH: Expanded G360 Panel Approved Earlier Than Expected; ADLT Timeline Potentially Accelerates

Life Science Tools & Diagnostics

FLASH

FLASH: GUARDANT HEALTH, INC. (GH) May 20, 2026

GH: Expanded G360 Panel Approved Earlier Than Rating:

Expected; ADLT Timeline Potentially Accelerates Outperform

Price:

$98.19

Price Target:

Our Take $120

The FDA has approved the expanded Guardant360 panel. This comes earlier than % Upside: 22.2%

our prior expectation for an H2:26 approval. In our view, the earlier-than-expected

approval likely accelerates the pathway to broader ADLT-based reimbursement, Source: FactSet, Wolfe Research

potentially as early as late 2026. As a result, we believe there is potentially Priced as of 05/19/26

material upside to the G360 LRP provided at GH's analyst day last fall.

What Happened?

GH announced FDA approval of Guardant360 Liquid CDx, which the company Doug Schenkel

describes as the “largest FDA-approved liquid biopsy panel,” with a ~100x wider dschenkel@wolferesearch.com

genomic footprint versus the prior Guardant360 CDx assay. The updated test (617) 458-7820

View Doug’s Researchintegrates genomic + epigenomic profiling and transfers over the prior seven FDA- View GH Model

approved CDx indications. View Comp Table

What is the Context? Colleen Babington, PhD

cbabington@wolferesearch.com

In 2024, GH updated the Guardant360 platform with expanded Smart Platform / (617) 458-7819

multi-omic capabilities, and since launch, management has increasingly framed the Austin Kennedy

next leg of G360 growth around the broader panel, epigenomic integration, and Smart akennedy@wolferesearch.com 617-458-7817

app functionality. We believe these capabilities are driving incremental adoption and